423 related articles for article (PubMed ID: 34328191)
1. Dysbiosis and liver diseases (Review).
Nishikawa H; Fukunishi S; Asai A; Yokohama K; Ohama H; Nishiguchi S; Higuchi K
Int J Mol Med; 2021 Sep; 48(3):. PubMed ID: 34328191
[TBL] [Abstract][Full Text] [Related]
2. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
[TBL] [Abstract][Full Text] [Related]
3. Role of gut microbiota in liver disease.
Albhaisi SAM; Bajaj JS; Sanyal AJ
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G84-G98. PubMed ID: 31657225
[TBL] [Abstract][Full Text] [Related]
4. [The gut microbiome is important in chronic liver disease].
Christensen E
Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618372
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
6. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
7. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.
Hendrikx T; Schnabl B
J Intern Med; 2019 Jul; 286(1):32-40. PubMed ID: 30873652
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
[TBL] [Abstract][Full Text] [Related]
10. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
[TBL] [Abstract][Full Text] [Related]
11. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
Mungamuri SK; Vijayasarathy K
Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
[TBL] [Abstract][Full Text] [Related]
12. Intestinal microbiota in liver disease.
Haque TR; Barritt AS
Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
[TBL] [Abstract][Full Text] [Related]
13. Alcohol, liver disease and the gut microbiota.
Bajaj JS
Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
[TBL] [Abstract][Full Text] [Related]
14. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
Das BK
APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
[TBL] [Abstract][Full Text] [Related]
15. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
[TBL] [Abstract][Full Text] [Related]
16. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
17. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
18. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.
Liu J; Yang D; Wang X; Asare PT; Zhang Q; Na L; Shao L
Front Cell Infect Microbiol; 2022; 12():774335. PubMed ID: 35444959
[TBL] [Abstract][Full Text] [Related]
19. Gut Microbiota and Complications of Liver Disease.
Acharya C; Bajaj JS
Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
[TBL] [Abstract][Full Text] [Related]
20. Targeting Dysbiosis for the Treatment of Liver Disease.
Anand G; Zarrinpar A; Loomba R
Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
